Cargando…
COVID-19 vaccination challenges: A mini-review
The emergence of SARS-CoV-2 has led to the infection of many people across the globe, over six million deaths, and has placed an unprecedented burden on public health worldwide. The pandemic has led to the high-speed development and production of vaccines against the COVID-19, as vaccines can end th...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302531/ https://www.ncbi.nlm.nih.gov/pubmed/35512088 http://dx.doi.org/10.1080/21645515.2022.2066425 |
_version_ | 1784751651472539648 |
---|---|
author | Mohseni Afshar, Zeinab Barary, Mohammad Hosseinzadeh, Rezvan Karim, Bardia Ebrahimpour, Soheil Nazary, Kosar Sio, Terence T. Sullman, Mark J. M. Carson-Chahhoud, Kristin Moudi, Emaduddin Babazadeh, Arefeh |
author_facet | Mohseni Afshar, Zeinab Barary, Mohammad Hosseinzadeh, Rezvan Karim, Bardia Ebrahimpour, Soheil Nazary, Kosar Sio, Terence T. Sullman, Mark J. M. Carson-Chahhoud, Kristin Moudi, Emaduddin Babazadeh, Arefeh |
author_sort | Mohseni Afshar, Zeinab |
collection | PubMed |
description | The emergence of SARS-CoV-2 has led to the infection of many people across the globe, over six million deaths, and has placed an unprecedented burden on public health worldwide. The pandemic has led to the high-speed development and production of vaccines against the COVID-19, as vaccines can end the pandemic. At the beginning of the program, vaccinations were initially targeted only at high-risk groups, such as the elderly, those with comorbidities, or healthcare workers. Although most of the mentioned populations have received the two recommended doses, limited resources have left many authorities with an effective vaccine undersupply. Therefore, policies have been implemented to manage the available doses of the vaccines more efficiently. As there is no universally agreed consensus on this topic, we discuss the different recommendations and guidelines regarding the time interval between the two vaccine doses and explain the different scenarios for applying the two doses. |
format | Online Article Text |
id | pubmed-9302531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-93025312022-07-22 COVID-19 vaccination challenges: A mini-review Mohseni Afshar, Zeinab Barary, Mohammad Hosseinzadeh, Rezvan Karim, Bardia Ebrahimpour, Soheil Nazary, Kosar Sio, Terence T. Sullman, Mark J. M. Carson-Chahhoud, Kristin Moudi, Emaduddin Babazadeh, Arefeh Hum Vaccin Immunother Coronavirus – Mini-Review The emergence of SARS-CoV-2 has led to the infection of many people across the globe, over six million deaths, and has placed an unprecedented burden on public health worldwide. The pandemic has led to the high-speed development and production of vaccines against the COVID-19, as vaccines can end the pandemic. At the beginning of the program, vaccinations were initially targeted only at high-risk groups, such as the elderly, those with comorbidities, or healthcare workers. Although most of the mentioned populations have received the two recommended doses, limited resources have left many authorities with an effective vaccine undersupply. Therefore, policies have been implemented to manage the available doses of the vaccines more efficiently. As there is no universally agreed consensus on this topic, we discuss the different recommendations and guidelines regarding the time interval between the two vaccine doses and explain the different scenarios for applying the two doses. Taylor & Francis 2022-05-05 /pmc/articles/PMC9302531/ /pubmed/35512088 http://dx.doi.org/10.1080/21645515.2022.2066425 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Coronavirus – Mini-Review Mohseni Afshar, Zeinab Barary, Mohammad Hosseinzadeh, Rezvan Karim, Bardia Ebrahimpour, Soheil Nazary, Kosar Sio, Terence T. Sullman, Mark J. M. Carson-Chahhoud, Kristin Moudi, Emaduddin Babazadeh, Arefeh COVID-19 vaccination challenges: A mini-review |
title | COVID-19 vaccination challenges: A mini-review |
title_full | COVID-19 vaccination challenges: A mini-review |
title_fullStr | COVID-19 vaccination challenges: A mini-review |
title_full_unstemmed | COVID-19 vaccination challenges: A mini-review |
title_short | COVID-19 vaccination challenges: A mini-review |
title_sort | covid-19 vaccination challenges: a mini-review |
topic | Coronavirus – Mini-Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302531/ https://www.ncbi.nlm.nih.gov/pubmed/35512088 http://dx.doi.org/10.1080/21645515.2022.2066425 |
work_keys_str_mv | AT mohseniafsharzeinab covid19vaccinationchallengesaminireview AT bararymohammad covid19vaccinationchallengesaminireview AT hosseinzadehrezvan covid19vaccinationchallengesaminireview AT karimbardia covid19vaccinationchallengesaminireview AT ebrahimpoursoheil covid19vaccinationchallengesaminireview AT nazarykosar covid19vaccinationchallengesaminireview AT sioterencet covid19vaccinationchallengesaminireview AT sullmanmarkjm covid19vaccinationchallengesaminireview AT carsonchahhoudkristin covid19vaccinationchallengesaminireview AT moudiemaduddin covid19vaccinationchallengesaminireview AT babazadeharefeh covid19vaccinationchallengesaminireview |